Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Aprea Therapeutics

09/22/2021 | 05:15pm EST


© MT Newswires 2021
All news about APREA THERAPEUTICS, INC.
11/08Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on ..
PU
11/08APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/08Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/08Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on ..
GL
11/04Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
GL
11/04Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
GL
11/04Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
CI
11/03INSIDER SELL : Aprea Therapeutics
MT
10/15APREA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/15Aprea Therapeutics, Inc. Announces Resignation of Johan Christenson from the Board of D..
CI
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -37,9 M - -
Net cash 2021 56,0 M - -
P/E ratio 2021 -2,31x
Yield 2021 -
Capitalization 88,4 M 88,4 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 11
Free-Float 90,2%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 4,12 $
Average target price 4,33 $
Spread / Average Target 5,18%
EPS Revisions
Managers and Directors
Christian S. Schade Chairman, President & Chief Executive Officer
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Bernd Robert Seizinger Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-16.26%88
MODERNA, INC.171.27%114 904
LONZA GROUP AG30.52%59 816
IQVIA HOLDINGS INC.51.92%51 999
SEAGEN INC.-14.61%27 346
CELLTRION, INC.-42.20%24 169